Under the terms of the agreement, Astellas will provide funding for the collaboration and the work will be performed at ReForm Biologics’ facilities in Woburn, MA.
“We are excited to initiate this collaboration with Astellas, a global leader in turning innovative science into value for patients. We appreciate the efforts of Astellas Innovation Management team in getting the agreement completed,” said John Sorvillo, chief executive officer, ReForm Biologics. “This collaboration will demonstrate how new formulation technologies can optimize dosing and support life cycle management in pharmaceutical drug development programs. We look forward to working with Astellas to support the development of this clinical-stage asset.”